Ionis Pharmaceuticals (FRA:ISI) Long-Term Debt: €1,167.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
71 GF Score
Price €49.90
GF Value €47.58
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Long-Term Debt?

Ionis Pharmaceuticals FRA:ISI +2.46% 71 Long-Term Debt is €1,167.1 Mil as of Mar. 2026. GuruFocus rates FRA:ISI with a GF Score™ of 71/100 and a GF Value™ of €47.58 (Fairly Valued). The stock has 6 warning signs investors should review.

Ionis Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was €1,167.1 Mil.

Ionis Pharmaceuticals's quarterly Long-Term Debt increased from Sep. 2025 (€507.7 Mil) to Dec. 2025 (€1,150.7 Mil) and increased from Dec. 2025 (€1,150.7 Mil) to Mar. 2026 (€1,167.1 Mil).

Ionis Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 (€1,127.5 Mil) to Dec. 2024 (€1,189.4 Mil) but then declined from Dec. 2024 (€1,189.4 Mil) to Dec. 2025 (€1,150.7 Mil).

Ionis Pharmaceuticals  (FRA:ISI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ionis Pharmaceuticals Long-Term Debt Related Terms

Ionis Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Long-Term Debt Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,086.86 1,116.49 1,127.45 1,189.44 1,150.72

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,156.91 542.30 507.71 1,150.72 1,167.09
FRA:ISI
71GF Score
Ionis Pharmaceuticals Inc FRA:ISI
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €1,167.1 Mil mean?
Ionis Pharmaceuticals (FRA:ISI) has a Long-Term Debt of €1,167.1 Mil as of Mar. 2026.
Is Ionis Pharmaceuticals' Long-Term Debt too high?
Ionis Pharmaceuticals' current Long-Term Debt is €1,167.1 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Long-Term Debt compare to KYMR and PRAX?
Ionis Pharmaceuticals' Long-Term Debt of €1,167.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ionis Pharmaceuticals's current Long-Term Debt is €1,167.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Fairly Valued. The stock's GF Value™ is €47.58, compared to a current price of €49.90 — trading 4.9% above its estimated fair value. The current Long-Term Debt is €1,167.1 Mil. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current Long-Term Debt is €1,167.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €49.90 is trading 4.9% above its estimated GF Value™ of €47.58. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:ISI:

  • Long-Term Debt: €1,167.1 Mil
  • GF Value™: €47.58 vs. price of €49.90 (4.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for FRA:ISI

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.90
Price
€47.58
GF Value